Innovation Pharmaceuticals Inc (IPIX)

[Orion Nebula]

BioHedge - Thanks for posting this. It is a great article and I forwarded it to a friend of mine diagnosed with lung cancer. What I found interesting is that the approach described is targeting the several mutations of lung cancer as opposed to K where potentially any mutation might be "fixed" either through apoptosis or correction of the error. The early work with K indicates it was perhaps most effective with lung cancer, which is very encouraging as it has been a largely intractable disease. Another aspect that is encouraging about K is in regards to the part of the article describing how some of the tumors work around the new targeted drug and come back with a vengeance. If the MOA of K works as described, that will not happen as the aberrant tumor cell will be dead or restored to its original benign function. So while the drugs described in the article sound great and indicate a huge step forward, I think K has a real chance to go beyond even what they offer. And that is saying something!